Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 27, 2021

Primary Completion Date

February 2, 2027

Study Completion Date

February 2, 2027

Conditions

Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic MelanomaPathologic Stage IV Cutaneous Melanoma AJCC v8

Interventions

DRUG

Binimetinib

Given PO

DRUG

Encorafenib

Given PO

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER